|
| Power your data-science drug discovery Introducing the QIAGEN Biomedical Knowledge Base. The first expertly curated knowledge base that comes from high-quality manually curated content with granularity and causality that spans multiple domains. Learn more |
Merck's C-suite shakeup logs another loss as marketing exec Garay leaves for Moderna BridgeBio strategy head departs amid company’s second round of layoffs this year Boston Scientific surges 10% in Q1 amid slew of FDA nods, company reorganization Walmart heir's nonprofit teams with Washington Regional to build new medical system in northwest Arkansas Future shaky at Solid Bio as it shaves off 35% of workforce, chief operating officer plans exit Pfizer and Biohaven clinch migraine approval in Europe, beating AbbVie to key market Still looking to trim the fat, Acutus sells line of heart devices to Medtronic for $50M upfront Former OptumRx CEO launches drug pricing startup with GV-led $35M round GlaxoSmithKline's sales soar thanks to Shingrix, COVID-19 antibody but oncology lags Abbott launches diabetes team-up with Ypsomed, CamDiab to bring artificial pancreas system to Europe UPDATE: Amgen opts to DARP-out after seeing early data from $550M Molecular Partners biobucks collab Broussard: Humana making headway in updating approach to MA sales after underwhelming open enrollment Sensyne’s new CEO kicks off restructuring with potential mass layoffs, sale of several divisions Featured Story | By Fraiser Kansteiner On May 31, Arpa Garay will enter the Moderna fold as chief commercial officer, the company said Wednesday. She's leaving just two months after nabbing a promotion at Merck & Co. read more |
| |
|---|
|
Top Stories By Max Bayer BridgeBio is cutting staff for the second time this year as the company continues to reel from a phase 3 defeat in December. At the same time, the company's chief strategy officer is headed for the exit. read more By Andrea Park Boston Scientific may have slimmed down its sprawling corporate structure in the first quarter of the year, but that didn’t keep it from plumping up its earnings for the period. read more By Anastassia Gliadkovskaya The goal is to expand access to specialty care and train a new generation of health professionals beyond general medicine. read more By Gabrielle Masson Things are anything but stable at Solid Biosciences, a life sciences company targeting therapies for Duchenne muscular dystrophy, as it plans to cut over a third of its workforce—for the second time in two years—and Chief Operating Officer Joel Schneider, Ph.D., departs. read more By Fraiser Kansteiner Looking to reach patients with a wide range of migraine symptoms in Europe, Pfizer and Biohaven are first on the scene with an oral CGRP drug approval. read more By Andrea Park If there’s a name for the much less exciting inverse of a shopping spree, Acutus Medical is on it. read more By Rebecca Torrence Former OptumRx CEO Mark Thierer is launching drug pricing startup Waltz Health with $35 million in funding led by GV (Google Ventures). read more By Angus Liu Ever since the pandemic started holding back GlaxoSmithKline’s Shingrix, the company has repeatedly said its flagship shingles vaccine will return to growth. Now, the British pharma giant has gotten a taste of what that rebound will look like—even though CEO Emma Walmsley still warns of speed bumps ahead. read more By Conor Hale The FreeStyle Libre 3's blood sugar readings will be fed to a Ypsomed insulin pump and a mobile app developed by the University of Cambridge. read more By Annalee Armstrong After a peak at the earliest data for Molecular Partners’ DARPin therapy, Amgen is saying thanks but no thanks on the $550 million partnership. The company's Novartis-partnered COVID-19 therapy is also delayed. read more By Paige Minemyer Revenues were also up by double digits from the prior-year quarter, hitting $24 billion. read more By Andrea Park Barely a week into his tenure, Alex Snow, the newly appointed CEO of Sensyne Health, is already shaking things up at the troubled company. read more |
